8-K: BullFrog AI Faces Nasdaq Delisting Threat

BullFrog AI Holdings, Inc. received a notice from Nasdaq indicating non-compliance with listing rules, potentially leading to delisting.

Summary

• BullFrog AI Holdings, Inc. (BFRG) received a notice from Nasdaq on February 19, 2026, stating that it failed to meet the terms of an extension to comply with the Nasdaq Listing Rule 5550(b)(1).
• The rule requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders' equity.
• The company had previously received an initial non-compliance notice on August 21, 2025, and submitted a plan to regain compliance on September 30, 2025.
• Nasdaq granted an extension until February 17, 2026, based on the company's plan.
• The company's securities are now subject to delisting unless it timely requests a hearing before an independent Nasdaq Hearings Panel.
• BullFrog AI intends to request a hearing, which will automatically stay any suspension or delisting action.
• At the hearing, the company plans to present additional details of its compliance plan and request more time to regain compliance.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a significantly negative development, as the company has failed to meet a critical listing requirement and is now facing delisting, which carries substantial risks for its market presence and ability to raise capital.

Negatives

• The company has failed to meet Nasdaq's minimum $2,500,000 stockholders' equity requirement.
• Nasdaq has determined that the company did not meet the terms of its previously granted extension.
• The company's securities are now subject to delisting from The Nasdaq Stock Market LLC.
• Delisting could make it more difficult to buy or sell the company's common stock and warrants.
• Delisting could lead to a material decline in the price of the company's common stock and warrants.
• Delisting could impair the company's ability to raise capital.

Risks

• There is no assurance that the Nasdaq Hearings Panel will grant the company's request for additional time to regain compliance.
• Even if an extension is granted, there is no assurance that the company will be able to regain compliance with applicable Nasdaq listing requirements.
• Delisting from Nasdaq would negatively impact the liquidity and market price of the company's securities.
• Delisting could severely hinder the company's future capital-raising efforts.

Future Outlook

The company intends to request a hearing before the Nasdaq Hearings Panel to present its plan and seek additional time to regain compliance. However, there is no assurance that the Panel will grant this request or that the company will ultimately be able to meet Nasdaq's listing requirements.

Management Comments

• The Company intends to timely submit a request for a hearing before the Panel.
• The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any extension period granted by the Panel following the hearing.
• At the hearing, the Company plans to present additional details of the Companys Plan and provide an update on its efforts to regain compliance.
• The Company will also request additional time to complete the steps of its Plan and regain compliance with all applicable Nasdaq Listing Rules.

Industry Context

StockSavvy.ai notes that non-compliance with listing standards, particularly related to financial metrics like stockholders' equity, is a common challenge for smaller or emerging growth companies, especially in volatile market conditions or during periods of significant investment in R&D without immediate revenue generation. Maintaining Nasdaq listing is crucial for liquidity and investor confidence, distinguishing listed companies from those on over-the-counter markets.

Comparison to Industry Standards

• Maintaining a minimum stockholders' equity of $2,500,000 is a standard requirement for continued listing on The Nasdaq Capital Market, a benchmark that BullFrog AI has failed to meet.
• Companies like Bio-Path Holdings (BPTH) and Soligenix (SNGX) have also faced Nasdaq compliance issues related to minimum bid price or stockholders' equity in the past, often requiring reverse stock splits or capital raises to regain compliance.
• The ability to maintain listing standards is a key indicator of financial stability and operational health compared to peers in the biotech or AI-driven drug discovery sector, where capital burn rates can be high.

Stakeholder Impact

• Shareholders: Potential for significant share price decline, reduced liquidity, and increased difficulty in buying or selling shares if delisted.
• Investors: Increased risk due to uncertainty regarding the company's listing status and future capital-raising capabilities.
• Company Management: Faces the immediate challenge of preparing for and presenting a compelling case to the Nasdaq Hearings Panel to avoid delisting.

Next Steps

• Timely submit a request for a hearing before the Nasdaq Hearings Panel.
• Present additional details of the company's plan to regain compliance at the hearing.
• Provide an update on efforts to regain compliance at the hearing.
• Request additional time from the Panel to complete the steps of its plan and regain compliance with all applicable Nasdaq Listing Rules.

Key Dates

Recommendation

The company's failure to meet Nasdaq's continued listing requirements and the subsequent delisting threat represent a severe negative event. This situation introduces significant uncertainty, liquidity risk, and potential for substantial share price depreciation. The ability to raise capital will also be severely impaired. Seasoned investors would likely view this as a strong sell signal due to the immediate and long-term adverse implications for the company's market viability.

Keywords

Nasdaq delisting, stockholders equity, listing compliance, BFRG, Nasdaq Capital Market, SEC filing, corporate governance, financial compliance